188 related articles for article (PubMed ID: 32817292)
1. Molecular attributes underlying central nervous system and systemic relapse in diffuse large B-cell lymphoma.
Isaev K; Ennishi D; Hilton L; Skinnider B; Mungall KL; Mungall AJ; Bakhtiari M; Tremblay-LeMay R; Silva A; Ben-Neriah S; Boyle M; Villa D; Marra MA; Steidl C; Gascoyne RD; Morin R; Savage KJ; Scott DW; Kridel R
Haematologica; 2021 May; 106(5):1466-1471. PubMed ID: 32817292
[No Abstract] [Full Text] [Related]
2. Central nervous system prophylaxis in diffuse large B-cell lymphoma: a race to the bottom.
Roschewski M
Haematologica; 2021 Feb; 106(2):332-334. PubMed ID: 33522784
[No Abstract] [Full Text] [Related]
3. Highly elevated serum lactate dehydrogenase is associated with central nervous system relapse in patients with diffuse large B-cell lymphoma: Results of a multicenter prospective cohort study.
Kim SJ; Hong JS; Chang MH; Kim JA; Kwak JY; Kim JS; Yoon DH; Lee WS; Do YR; Kang HJ; Eom HS; Park Y; Won JH; Mun YC; Kim HJ; Kwon JH; Kong JH; Oh SY; Lee S; Bae SH; Yang DH; Jun HJ; Kim YS; Yun HJ; Lee SI; Kim MK; Park EK; Kim WS; Suh C
Oncotarget; 2016 Nov; 7(44):72033-72043. PubMed ID: 27713132
[TBL] [Abstract][Full Text] [Related]
4. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
[TBL] [Abstract][Full Text] [Related]
5. About time: why central nervous system prophylaxis timing in diffuse large B-cell lymphoma matters and does the protocol need updating?
Lewis KL; Cheah CY
Expert Rev Hematol; 2022 Nov; 15(11):959-962. PubMed ID: 36278876
[No Abstract] [Full Text] [Related]
6. Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study.
Holte H; Leppä S; Björkholm M; Fluge O; Jyrkkiö S; Delabie J; Sundström C; Karjalainen-Lindsberg ML; Erlanson M; Kolstad A; Fosså A; Ostenstad B; Löfvenberg E; Nordström M; Janes R; Pedersen LM; Anderson H; Jerkeman M; Eriksson M
Ann Oncol; 2013 May; 24(5):1385-92. PubMed ID: 23247661
[TBL] [Abstract][Full Text] [Related]
7. Dosage of high-dose methotrexate as CNS prophylaxis in DLBCL: A detailed analysis of toxicity and impact on CNS relapse.
Wilson MR; Kirkwood AA; Wong Doo N; Soussain C; Choquet S; Lees C; Fox C; Preston G; Ahearne M; Strüßmann T; Clavert A; Rusconi C; Ku M; Khwaja J; Narkhede M; Lewis K; Durot E; Smith J; Renaud L; Ferreri AJM; El-Galaly T; Cwynarski K; McKay P; Eyre TA
Am J Hematol; 2024 Feb; 99(2):E46-E50. PubMed ID: 38037530
[No Abstract] [Full Text] [Related]
8. Proteomics uncovers molecular features for relapse risk stratification in patients with diffuse large B-cell lymphoma.
Ludvigsen M; Campbell AJ; Enemark MB; Hybel TE; Karjalainen-Lindsberg ML; Beiske K; Bjerre M; Pedersen LM; Holte H; Leppä S; Jørgensen JM; Honoré B
Blood Cancer J; 2023 Oct; 13(1):161. PubMed ID: 37884514
[No Abstract] [Full Text] [Related]
9. Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy.
Villa D; Connors JM; Shenkier TN; Gascoyne RD; Sehn LH; Savage KJ
Ann Oncol; 2010 May; 21(5):1046-52. PubMed ID: 19861575
[TBL] [Abstract][Full Text] [Related]
10. Development of JAK2V617F-positive polycythemia vera after chemotherapy-induced remission of primary central nervous system diffuse large B cell non-Hodgkin's lymphoma: a case report and review of the literature.
Elli EM; Belotti A; Cecchetti C; Realini S; Fedele M; Parma M; Pogliani EM
Acta Haematol; 2013; 130(3):142-5. PubMed ID: 23652352
[TBL] [Abstract][Full Text] [Related]
11. A Rare Case of Spontaneous Remission and Relapse of a Primary Central Nervous System Lymphoma.
Ramos R; Fernandes JS; Almeida M; Almeida R
Acta Med Port; 2018 Dec; 31(12):777-783. PubMed ID: 30684376
[TBL] [Abstract][Full Text] [Related]
12. Central nervous system involvement of primary cutaneous diffuse large B cell lymphoma-leg type diagnosed according to the WHO 2008 classification.
Aoki K; Arima H; Tabata S; Matsushita A; Ishikawa T; Takahashi T
Ann Hematol; 2012 Dec; 91(12):1975-6. PubMed ID: 22592652
[No Abstract] [Full Text] [Related]
13. Impact of rituximab on incidence of and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: a systematic review and meta-analysis.
Zhang J; Chen B; Xu X
Leuk Lymphoma; 2014 Mar; 55(3):509-14. PubMed ID: 23741977
[TBL] [Abstract][Full Text] [Related]
14. Intrathecal methotrexate prophylaxis and central nervous system relapse in patients with diffuse large B-cell lymphoma following rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone.
Tomita N; Takasaki H; Ishiyama Y; Kishimoto K; Ishibashi D; Koyama S; Ishii Y; Takahashi H; Numata A; Watanabe R; Tachibana T; Ohshima R; Hagihara M; Hashimoto C; Takemura S; Taguchi J; Fujimaki K; Sakai R; Motomura S; Ishigatsubo Y
Leuk Lymphoma; 2015 Mar; 56(3):725-9. PubMed ID: 24913502
[TBL] [Abstract][Full Text] [Related]
15. Site of central nervous system (CNS) relapse in patients with diffuse large B-cell lymphoma (DLBCL) by the CNS-IPI risk model.
Kansara R; Villa D; Gerrie AS; Klasa R; Shenkier T; Scott DW; Slack GW; Gascoyne RD; Connors JM; Sehn LH; Savage KJ
Br J Haematol; 2017 Nov; 179(3):508-510. PubMed ID: 27443424
[No Abstract] [Full Text] [Related]
16. Cell-free DNA sequencing as a potential screening tool for phase I targeted treatment in refractory/relapse diffuse large B-cell lymphoma.
Quivoron C; Tarabay A; Michot JM; Pagès A; Lecourt H; Aupérin A; Danu A; Lazarovici J; Rossignol J; Ghez D; Dartigues P; Vergé V; Massard C; Camara-Clayette V; Ribrag V; Sarkozy C
Haematologica; 2022 Aug; 107(8):1928-1932. PubMed ID: 35320922
[No Abstract] [Full Text] [Related]
17. Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL.
Klanova M; Sehn LH; Bence-Bruckler I; Cavallo F; Jin J; Martelli M; Stewart D; Vitolo U; Zaja F; Zhang Q; Mattiello F; Sellam G; Punnoose EA; Szafer-Glusman E; Bolen CR; Oestergaard MZ; Fingerle-Rowson GR; Nielsen T; Trneny M
Blood; 2019 Feb; 133(9):919-926. PubMed ID: 30617197
[TBL] [Abstract][Full Text] [Related]
18. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
[TBL] [Abstract][Full Text] [Related]
19. Clinical Effect of CD25 on the Prognosis of Diffuse Large B Cell Lymphoma with Secondary Central Nervous System Relapse.
Oka S; Ono K; Nohgawa M
Pathol Oncol Res; 2020 Jul; 26(3):1843-1850. PubMed ID: 31768966
[TBL] [Abstract][Full Text] [Related]
20. CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP.
Schmitz N; Zeynalova S; Nickelsen M; Kansara R; Villa D; Sehn LH; Glass B; Scott DW; Gascoyne RD; Connors JM; Ziepert M; Pfreundschuh M; Loeffler M; Savage KJ
J Clin Oncol; 2016 Sep; 34(26):3150-6. PubMed ID: 27382100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
